Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and RadiotherapyJean Louis Lefèbvre, Frédéric Rolland, Margot Tesselaar et al.|JNCI Journal of the National Cancer Institute|2009Cited by 282
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trialJ. Guigay, Franck Darloy, Damien Vansteene et al.|The Lancet Oncology|2021Cited by 231
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancerEzra E.W. Cohen, J.-P. Machiels, Lisa Licitra et al.|Annals of Oncology|2017Cited by 80
Long-term update of the 24954 EORTC phase III trial on larynx preservationB. Henriques de Figueiredo, Vincent Grégoire, Catherine Fortpied et al.|European Journal of Cancer|2016Cited by 45
MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patientsMathilde Saint‐Ghislain, Manuel Rodrigues, Anne‐Céline Derrien et al.|European Journal of Cancer|2022Cited by 37